388 related articles for article (PubMed ID: 25452614)
1. Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation.
Shah NN; Baird K; Delbrook CP; Fleisher TA; Kohler ME; Rampertaap S; Lemberg K; Hurley CK; Kleiner DE; Merchant MS; Pittaluga S; Sabatino M; Stroncek DF; Wayne AS; Zhang H; Fry TJ; Mackall CL
Blood; 2015 Jan; 125(5):784-92. PubMed ID: 25452614
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for graft-versus-host-disease after donor lymphocyte infusion following T-cell depleted allogeneic stem cell transplantation.
Koster EAS; von dem Borne PA; van Balen P; Marijt EWA; Tjon JML; Snijders TJF; van Lammeren D; Veelken H; Falkenburg JHF; Halkes CJM; de Wreede LC
Front Immunol; 2024; 15():1335341. PubMed ID: 38545096
[TBL] [Abstract][Full Text] [Related]
3. Early recovery of natural killer cells post T-cell depleted allogeneic stem cell transplantation using alemtuzumab "in the bag".
Davison GM; Opie JJ; Davids SFG; Mohammed R; Novitzky N
Transpl Immunol; 2024 Jun; 84():102045. PubMed ID: 38641148
[TBL] [Abstract][Full Text] [Related]
4. NK cells produce high levels of IL-10 early after allogeneic stem cell transplantation and suppress development of acute GVHD.
Chan YLT; Zuo J; Inman C; Croft W; Begum J; Croudace J; Kinsella F; Maggs L; Nagra S; Nunnick J; Abbotts B; Craddock C; Malladi R; Moss P
Eur J Immunol; 2018 Feb; 48(2):316-329. PubMed ID: 28944953
[TBL] [Abstract][Full Text] [Related]
5. The role and novel use of natural killer cells in graft-versus-leukemia reactions after allogeneic transplantation.
Hadjis AD; McCurdy SR
Front Immunol; 2024; 15():1358668. PubMed ID: 38817602
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Inducers of Natural Killer cell Killing (ThINKK): preclinical assessment of safety and efficacy in allogeneic hematopoietic stem cell transplant settings.
Poirier N; Paquin V; Leclerc S; Lisi V; Marmolejo C; Affia H; Cordeiro P; Théorêt Y; Haddad E; Andelfinger G; Lavallée VP; Duval M; Herblot S
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38754915
[TBL] [Abstract][Full Text] [Related]
7. Recipient leukocyte infusion enhances the local and systemic graft-versus-neuroblastoma effect of allogeneic bone marrow transplantation in mice.
Willems L; Fevery S; Sprangers B; Rutgeerts O; Lenaerts C; Ibrahimi A; Gijsbers R; Van Gool S; Waer M; Billiau AD
Cancer Immunol Immunother; 2013 Nov; 62(11):1733-44. PubMed ID: 24081484
[TBL] [Abstract][Full Text] [Related]
8. Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation.
Rizzieri DA; Storms R; Chen DF; Long G; Yang Y; Nikcevich DA; Gasparetto C; Horwitz M; Chute J; Sullivan K; Hennig T; Misra D; Apple C; Baker M; Morris A; Green PG; Hasselblad V; Chao NJ
Biol Blood Marrow Transplant; 2010 Aug; 16(8):1107-14. PubMed ID: 20188202
[TBL] [Abstract][Full Text] [Related]
9. Early Reconstitution of NK and γδ T Cells and Its Implication for the Design of Post-Transplant Immunotherapy.
de Witte MA; Sarhan D; Davis Z; Felices M; Vallera DA; Hinderlie P; Curtsinger J; Cooley S; Wagner J; Kuball J; Miller JS
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1152-1162. PubMed ID: 29505821
[TBL] [Abstract][Full Text] [Related]
10. Combining Immunocytokine and
Bates PD; Rakhmilevich AL; Cho MM; Bouchlaka MN; Rao SL; Hales JM; Orentas RJ; Fry TJ; Gilles SD; Sondel PM; Capitini CM
Front Immunol; 2021; 12():668307. PubMed ID: 34489927
[TBL] [Abstract][Full Text] [Related]
11. Phase I dose escalation study of naive T-cell depleted donor lymphocyte infusion following allogeneic stem cell transplantation.
Maung KK; Chen BJ; Barak I; Li Z; Rizzieri DA; Gasparetto C; Sullivan KM; Long GD; Engemann AM; Waters-Pick B; Nichols KR; Lopez R; Kang Y; Sarantopoulos S; Sung AD; Chao NJ; Horwitz ME
Bone Marrow Transplant; 2021 Jan; 56(1):137-143. PubMed ID: 32624583
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of adoptive cell transfer with mixed-profile type-I/type-II allogeneic T cells for metastatic breast cancer.
Hardy NM; Mossoba ME; Steinberg SM; Fellowes V; Yan XY; Hakim FT; Babb RR; Avila D; Gea-Banacloche J; Sportès C; Levine BL; June CH; Khuu HM; Carpenter AE; Krumlauf MC; Dwyer AJ; Gress RE; Fowler DH; Bishop MR
Clin Cancer Res; 2011 Nov; 17(21):6878-87. PubMed ID: 21948234
[TBL] [Abstract][Full Text] [Related]
13. Generation of Non-Alloreactive Antiviral Central Memory CD8 Human Veto T Cells for Cell Therapy.
Bachar-Lustig E; Lask A; Eidelstein Y; Or-Geva N; Gidron-Budovsky R; Nathansohn-Levy B; Eyrich M; Liu WH; Dang G; Miranda KC; Ramirez A; Kaur I; Rezvani K; Shpall E; Champlin RE; Nagler A; Shimoni A; Barnees-Kagan S; Reisner Y
Transplant Cell Ther; 2024 Jan; 30(1):71.e1-71.e13. PubMed ID: 37890590
[TBL] [Abstract][Full Text] [Related]
14. Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy.
Berrien-Elliott MM; Becker-Hapak M; Cashen AF; Jacobs M; Wong P; Foster M; McClain E; Desai S; Pence P; Cooley S; Brunstein C; Gao F; Abboud CN; Uy GL; Westervelt P; Jacoby MA; Pusic I; Stockerl-Goldstein KE; Schroeder MA; DiPersio JF; Soon-Shiong P; Miller JS; Fehniger TA
Blood; 2022 Feb; 139(8):1177-1183. PubMed ID: 34797911
[TBL] [Abstract][Full Text] [Related]
15. Polymorphism in the interleukin-7 receptor-alpha and outcome after allogeneic hematopoietic cell transplantation with matched unrelated donor.
Shamim Z; Spellman S; Haagenson M; Wang T; Lee SJ; Ryder LP; Müller K
Scand J Immunol; 2013 Aug; 78(2):214-20. PubMed ID: 23692589
[TBL] [Abstract][Full Text] [Related]
16. T-cell depleted allogeneic hematopoietic cell transplants as a platform for adoptive therapy with leukemia selective or virus-specific T-cells.
O'Reilly RJ; Koehne G; Hasan AN; Doubrovina E; Prockop S
Bone Marrow Transplant; 2015 Jun; 50 Suppl 2(Suppl 2):S43-50. PubMed ID: 26039207
[TBL] [Abstract][Full Text] [Related]
17. Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells.
Bachanova V; Sarhan D; DeFor TE; Cooley S; Panoskaltsis-Mortari A; Blazar BR; Curtsinger JM; Burns L; Weisdorf DJ; Miller JS
Cancer Immunol Immunother; 2018 Mar; 67(3):483-494. PubMed ID: 29218366
[TBL] [Abstract][Full Text] [Related]
18. Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant.
Bednarski JJ; Zimmerman C; Berrien-Elliott MM; Foltz JA; Becker-Hapak M; Neal CC; Foster M; Schappe T; McClain E; Pence PP; Desai S; Kersting-Schadek S; Wong P; Russler-Germain DA; Fisk B; Lie WR; Eisele J; Hyde S; Bhatt ST; Griffith OL; Griffith M; Petti AA; Cashen AF; Fehniger TA
Blood; 2022 Mar; 139(11):1670-1683. PubMed ID: 34871371
[TBL] [Abstract][Full Text] [Related]
19. "No donor"? Consider a haploidentical transplant.
Ciurea SO; Bayraktar UD
Blood Rev; 2015 Mar; 29(2):63-70. PubMed ID: 25307958
[TBL] [Abstract][Full Text] [Related]
20. In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity.
Nishimura R; Baker J; Beilhack A; Zeiser R; Olson JA; Sega EI; Karimi M; Negrin RS
Blood; 2008 Sep; 112(6):2563-74. PubMed ID: 18565854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
